IRIS
MINARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.316
AS - Asia 1.803
EU - Europa 1.685
SA - Sud America 293
AF - Africa 105
OC - Oceania 2
Totale 6.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.265
SG - Singapore 760
IT - Italia 620
CN - Cina 489
BR - Brasile 230
IE - Irlanda 215
HK - Hong Kong 182
SE - Svezia 170
DE - Germania 161
VN - Vietnam 106
NL - Olanda 91
RU - Federazione Russa 84
GB - Regno Unito 71
IN - India 64
ZA - Sudafrica 62
FR - Francia 55
AT - Austria 54
FI - Finlandia 51
BD - Bangladesh 33
CA - Canada 29
TR - Turchia 26
AR - Argentina 25
CI - Costa d'Avorio 23
KR - Corea 23
JP - Giappone 22
CZ - Repubblica Ceca 20
ID - Indonesia 20
ES - Italia 17
PL - Polonia 17
IQ - Iraq 15
MX - Messico 15
PK - Pakistan 14
IR - Iran 12
BE - Belgio 10
EC - Ecuador 10
UA - Ucraina 10
CO - Colombia 9
LT - Lituania 7
LU - Lussemburgo 7
PY - Paraguay 7
UZ - Uzbekistan 7
CL - Cile 5
BG - Bulgaria 4
EG - Egitto 4
IL - Israele 4
KZ - Kazakistan 4
MA - Marocco 4
RO - Romania 4
SN - Senegal 4
TN - Tunisia 4
AZ - Azerbaigian 3
DK - Danimarca 3
JO - Giordania 3
MK - Macedonia 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BW - Botswana 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
VE - Venezuela 2
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
Totale 6.204
Salva come PNG Salva come JPEG
Città #
Dallas 443
Singapore 422
Ashburn 420
Dublin 210
Chandler 200
Hong Kong 175
Parma 168
Santa Clara 157
Beijing 109
Boardman 96
Munich 90
Milan 85
Ann Arbor 84
Hefei 76
Shanghai 76
Los Angeles 72
Johannesburg 59
New York 58
Vienna 42
Ho Chi Minh City 41
Bologna 38
Moscow 34
Chicago 30
Hanoi 28
Marseille 27
Verona 25
Abidjan 23
Buffalo 22
Princeton 22
São Paulo 22
Seoul 21
London 20
Tokyo 19
Nuremberg 18
Denver 17
Frankfurt am Main 17
Helsinki 17
Turku 17
Dearborn 16
West Jordan 16
Warsaw 15
Atlanta 14
Bengaluru 14
Bremen 14
Columbus 14
Jakarta 14
The Dalles 14
Amsterdam 13
Brno 13
Council Bluffs 13
Modena 12
Izmir 11
Pune 11
Brussels 10
Chennai 10
Des Moines 10
Houston 10
Rio de Janeiro 10
Rome 10
Wilmington 10
Brescia 9
Manchester 9
Montreal 9
Poplar 9
Redondo Beach 9
Stockholm 9
Toronto 9
Chongqing 8
Düsseldorf 8
Phoenix 8
Seattle 8
Belo Horizonte 7
Buenos Aires 7
Changsha 7
Fremont 7
Istanbul 7
Jinan 7
Pavia 7
Ravenna 7
Shenyang 7
Tashkent 7
Auburn 6
Brasília 6
Brooklyn 6
Busseto 6
Cascina 6
Florence 6
Kolkata 6
Olomouc 6
Orem 6
Redmond 6
Tianjin 6
Woodbridge 6
Bolzano 5
Boston 5
Guangzhou 5
Kyiv 5
Lahore 5
Malo 5
Nanchang 5
Totale 4.046
Salva come PNG Salva come JPEG
Nome #
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 218
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 205
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 200
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 183
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 175
Evidence fo Epigenetic Abnormalities of the Androgen Receptor Gene in Foreskin from Children with Hypospadias 172
227P Sexual dimorphism in immune profile of early and advanced NSCLC 170
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 163
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 161
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 154
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 145
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 143
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 136
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 136
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 133
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 129
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 126
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 125
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 123
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 121
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 120
A novel mutation in the nr0b1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children. 120
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 116
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 116
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 113
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 113
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 111
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 108
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 106
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 106
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 104
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 102
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 101
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 101
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 99
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 98
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 98
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 96
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 95
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 95
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 83
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 81
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 80
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 78
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 73
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 70
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 69
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 68
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 68
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 65
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 60
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 59
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 59
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 51
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 42
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 42
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 24
Totale 6.308
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.305
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.305
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202184 0 0 0 0 0 5 12 10 20 8 14 15
2021/2022215 19 8 10 16 11 2 43 10 17 3 20 56
2022/2023849 67 84 37 73 83 87 15 64 242 7 61 29
2023/2024656 30 24 15 28 58 89 62 35 36 70 86 123
2024/20251.895 101 105 144 152 165 146 151 108 170 165 164 324
2025/20262.380 376 372 692 419 470 51 0 0 0 0 0 0
Totale 6.308